Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
Status:
Completed
Trial end date:
2003-08-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine
hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged
6-17